MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Tardive dyskinesia(TD)"

  • 2017 International Congress

    Healthcare Utilization and Costs for Patients With Tardive Dyskinesia

    B. Carroll, T. Park, D. Irwin, S. Gandhi (Frazer, PA, USA)

    Objective: To assess healthcare utilization and costs pre- and post-tardive dyskinesia (TD) diagnosis in a sample of patients from the commercially insured and Medicare Supplemental…
  • 2017 International Congress

    Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Efficacy, Safety, and Tolerability of Fixed-Dose Deutetrabenazine for the Treatment of Tardive Dyskinesia

    K. Anderson, D. Stamler, M. Davis, S. Factor, R. Hauser, J. Isojärvi, J. Jimenez-Shahed, W. Ondo, H. Fernandez (Washington, DC, USA)

    Objective: To evaluate the efficacy, safety, and tolerability of deutetrabenazine in patients with tardive dyskinesia (TD). Background: AIM-TD is the second large 12-week, Phase III,…
  • 2017 International Congress

    Effect of Deutetrabenazine on QTcF Interval in the AIM-TD Study: a 12-Week, Phase III, Randomized, Double-Blind, Placebo-Controlled Study

    K. Anderson, D. Stamler, M. Davis, S. Factor, R. Hauser, J. Isojärvi, L. Jarskog, J. Jimenez-Shahed, R. Kumar, S. Ochudlo, W. Ondo, H. Fernandez (Washington, DC, USA)

    Objective: To evaluate the effect of deutetrabenazine (DTB) on QT interval prolongation in patients with tardive dyskinesia (TD) in the AIM-TD study. Background: TD is…
  • 2017 International Congress

    Tardive syndromes induced by coadministration of tramadol and sertralin

    H. Sarac, N. Bozina, N. Henigsberg, L. Bagaric-Krakan (Zagreb, Croatia)

    Objective: To illustrate the possible association of tardive syndromes (TS) and coadministration of tramadol and sertraline in three patients. Background: TS is delayed onset of…
  • 2017 International Congress

    Low Incidence of Extrapyramidal Symptoms in Subjects with Tardive Dyskinesia Receiving Long-Term Valbenazine (NBI-98854) Treatment

    S. Lessig, R. Kurlan, S. Factor, J. Burke, C. Wright, R. Jimenez, G. Liang (La Jolla, CA, USA)

    Objective: To assess the emergence of extrapyramidal symptoms (EPS) such as akathisia and parkinsonism in adults with a diagnosis of schizophrenia/schizoaffective disorder or mood disorder…
  • 2017 International Congress

    Laryngeal Tardive Dyskinesia in a Patient treated with Haldol

    R. Joseph, F. Amjad (Columbus, OH, USA)

    Objective: To describe the case of woman with post stroke hemiballism treated chronically with Haldol who developed laryngeal tardive dystonia and to review the current…
  • 2017 International Congress

    Drug-induced movement disorders: not a typical problem

    A. Vives-Rodriguez, A. Patel (New Haven, CT, USA)

    Objective: To characterize patients with neuroleptic drug-induced movement disorders (DIMD) referred to a single academic center Movement Disorders clinic, their causative medications and the indications…
  • 2016 International Congress

    Risk of movement disorders with antipsychotic drugs in patients with schizophrenia or depressive disorders

    M.V. Rey, L. Molina, B. Recinos, B. Paz, M. Rovelo, F.E. Rodriguez Elias, J. Calderon, A. Arellano, S. Pomata, S. Perez-Lloret, CA-APD Study Team (Buenos Aires, Argentina)

    Objective: To compare the risk of movement disorders with antipsychotic drugs (APDs) in patients suffering from Schizophrenia or Depressive Disorders. Background: APDs are well-known causes…
  • 2016 International Congress

    Propranolol therapy for tardive dyskinesia: A retrospective examination

    S.A. Factor, K.A. Armstrong, J.M. Hatcher-Martin (Atlanta, GA, USA)

    Objective: To examine the tolerability and effectiveness of propranolol in treating tardive dyskinesia (TD). Background: TD is a disabling, often irreversible, movement disorder that results…
  • 2016 International Congress

    A comparative study of clinical profile of patients of drug induced parkinsonism with idiopathic Parkinson’s disease

    S. Kushwaha, R. Mistry, A. Anthony, S. Khurana (Delhi, India)

    Objective: Drug induced parkinsonism (DIP), caused by various group of drugs, is second most common etiology of parkinsonism after Idiopathic Parkinson's disease (IPD). No major…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • #25179 (not found)
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley